News

Currently, Firdapse (amifampridine phosphate or 3,4-DAP phosphate) is in Phase III development and it will be provided at no cost until sometime following approval. Patient enrollment in the

This patent will extend VistaGen’s intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and

YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.

Through this partnership, BettrLife’s mobile health software will be integrated with Viridian’s Maestro population health management platform, allowing users to interact directly with Viridian health coaches. Through integration

TouchMD is an interactive software platform that helps specialty physicians engage patients in the education process before, during and after the consultation. The software allows physicians and staff

The new product line for the pharmaceutical industry expands the established EFLA brand, offering increased value to the pharmaceutical industry plus expertise in building a supply chain for

The drug was not evaluated in patients with MCD who are HIV positive or HHV-8 positive because it did not bind to virally produced interleukin-6 (IL-6) in a

Pure is part of the Elsevier Research Intelligence portfolio of tools and services. Over the years, UrFU, one of the leading Russian universities, has focused on increasing the

Both the companies’ have not disclosed the financial terms of the agreement. In July 2013, both the firms have entered into their first manufacturing agreement to collaborate in